Navivumab
Based on 1 Customer Validation
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.10%
- CAS 番号: 1443004-16-7
- 分子量:146.6 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 kappa
Virus
influenza A virus hemagglutinin HA
Nivolumab shows no immunohistochemical cross-reactivity with the entire panel of human tissues[3].
Nivolumab shows no immunohistochemical cross-reactivity with the entire tissue panel of cynomolgus monkeys[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 1443004-16-7
-
性状 Liquid
-
分子量 146.6 kDa
-
Color Colorless to light yellow
-
SMILES
[Navivumab]
-
別名
CT-P23
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)